Efficacy and Safety of Oral Treprostinil in Patients with Pulmonary Arterial Hypertension on Background Monotherapy or Dual Therapy
Advances in Therapy · 2026
DOI: 10.1007/s12325-026-03497-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Therapy, 2026. Verfasst von Daniel Lachant und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY, 14642, USA. daniel_lachant@…. Hauptthemen laut MEDLINE: Epoprostenol, Antihypertensive Agents, Hypertension, Pulmonary, Phosphodiesterase 5 Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: United Therapeutics Corporation.
Abstract (Originalsprache)
INTRODUCTION: Pulmonary arterial hypertension (PAH) is a progressive, often fatal disease characterized by an elevation in pulmonary arterial pressure and pulmonary vascular resistance (PVR). Oral treprostinil is indicated for the treatment of PAH and has been shown to delay disease progression and to improve exercise capacity. METHODS: The purpose of this report is to examine and summarize the data on the use of oral treprostinil in patients already on dual therapy with an endothelin receptor antagonist (ERA) and phosphodiesterase type-5 inhibitor (PDE-5i), using data from the FREEDOM-C study, FREEDOM-C2 study, and a retrospective chart review. RESULTS: In this analysis, background monotherapy versus dual therapy did not have an impact on clinical parameters (6-min walk distance). Additionally, the number of background therapies did not have an impact on the dose of oral treprostinil achieved at week 16 or measures typically used to assess clinical efficacy in patients with PAH (change in 6MWD at week 16 and NT-proBNP). CONCLUSION: Oral treprostinil is a safe and efficacious treatment option and has been shown to further improve clinical parameters and risk status in patients with PAH on background dual therapy. TRIAL REGISTRY: ClinicalTrials.gov identifier, NCT00325442 and NCT00887978.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary and Critical Care Medicine, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY, 14642, USA. daniel_lachant@urmc.rochester.edu.
- Cardiology-Advanced Heart Failure & Transplant, Allegheny General Hospital, 490 E North Ave Suite 307, Pittsburgh, PA, 15212, USA.
- Pulmonary Hypertension, Right Heart Failure, and CTEPH Program Heart and Vascular Institute, Temple University Lewis Katz School of Medicine, 3401 N. Broad Street, Philadelphia, PA, 19140, USA.
- University of California-Davis, 4150 V Street, PSSB Suite 3400, Sacramento, CA, 95817, USA.
- Valley Advanced Lung Diseases Institute, 7417 N Cedar Ave Ste 101, Fresno, CA, 93720, USA.
- Department of Pulmonary Medicine, Biomedical Research Networking Center on Respiratory Diseases (CIBERES, Hospital Clínic-IDIBAPS, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.
ORCID-Profile: Daniel Lachant
Förderung
- United Therapeutics Corporation
Zitieren
APA
Lachant, D., Raina, A., Krishnan, M., Sood, N., Balasubramanian, V., Barbera, J. A., Kiely, D. G., Lee, D., Wu, B., Hwang, S., Seaman, S., Broderick, M., & Elwing, J. (2026). Efficacy and Safety of Oral Treprostinil in Patients with Pulmonary Arterial Hypertension on Background Monotherapy or Dual Therapy. Advances in Therapy. https://doi.org/10.1007/s12325-026-03497-4
Vancouver
Lachant D, Raina A, Krishnan M, Sood N, Balasubramanian V, Barbera JA, et al. Efficacy and Safety of Oral Treprostinil in Patients with Pulmonary Arterial Hypertension on Background Monotherapy or Dual Therapy. Advances in Therapy. 2026. doi:10.1007/s12325-026-03497-4
BibTeX
@article{Lachant2026,
author = {Lachant, Daniel and Raina, Amresh and Krishnan, Mrinalini and Sood, Namita and Balasubramanian, Vijay and Barbera, Joan Albert and Kiely, David G and Lee, Dasom and Wu, Benjamin and Hwang, Stephanie and Seaman, Scott and Broderick, Meredith and Elwing, Jean},
title = {Efficacy and Safety of Oral Treprostinil in Patients with Pulmonary Arterial Hypertension on Background Monotherapy or Dual Therapy},
journal = {Advances in Therapy},
year = {2026},
doi = {10.1007/s12325-026-03497-4}
}
EUVIMED